PetMed Express Inc is a nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, foods, supplements, supplies, and vet services for dogs, cats, and horses. It markets and sells directly to consumers through its websites, toll-free numbers, and mobile application, offering convenience, price, speed of delivery, and customer service. It provides access to branded pharmaceuticals, generic medications, compounded prescription medications, over-the-counter health and wellness products, prescription and non-prescription food, pharmacy fulfillment, and AutoShip capabilities. Its digital platform offers pet healthcare solutions for chronic conditions, including allergies, arthritis, anxiety, kidney-related conditions, and hyperthyroidism.
Last trade$0.8752
Day change-$0.0225 (-2.51%)
Day range$0.856 – $0.911
Volume36,692
Market cap$20M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$20.01M
Price / earnings
—
Price / book
1.19×
Price / sales
0.12×
EV / sales
0.05×
EV / EBITDA
-0.49×
Profitability
Earnings per share
-$1.22
Return on assets
-45.78%
Return on equity
-161.27%
Dividend yield
0.01%
Liquidity and leverage
Debt / equity
0×
Current ratio
0.6×
Quick ratio
0.45×
Cash ratio
0.27×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$24.62M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PETS, quarterly periods
Line item
Q2 FY2027 Sep 30, 2026
Q1 FY2027 Jun 30, 2026
Q4 FY2026 Mar 31, 2026
Q3 FY2026 Dec 31, 2025
Q2 FY2026 Sep 30, 2025
Q1 FY2026 Jun 30, 2025
Q4 FY2025 Mar 31, 2025
Q3 FY2025 Dec 31, 2024
Revenue
$35.77M
$41.02M
$42.82M
$40.66M
$44.36M
$51.18M
$50.76M
$51.96M
Cost of revenue
$25.97M
$29.68M
$26.75M
$31.2M
$31.95M
$36.78M
$35.56M
$35.83M
Gross profit
$9.8M
$11.33M
$16.07M
$9.46M
$12.42M
$14.4M
$15.2M
$16.13M
Selling, general and administrative
$14.04M
$15.42M
$17.21M
$17.53M
$18.52M
$18.99M
$17.94M
$15M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$16.22M
$17.57M
$21.76M
$19.93M
$20.8M
$48.54M
$21.22M
$16.58M
Operating income
-$6.42M
-$6.23M
-$5.69M
-$10.47M
-$8.38M
-$34.13M
-$6.02M
-$450K
Interest expense
-$195K
-$338K
$0
$0
-$326K
-$198K
$0
$0
Income before taxes
-$6.42M
-$6.13M
-$4.16M
-$10.54M
-$8.51M
-$34.14M
-$5.98M
-$242K
Income taxes
$14K
$13K
-$102K
$11K
$9K
$9K
$5.66M
$465K
Net income
-$6.43M
-$6.15M
-$4.06M
-$10.55M
-$8.52M
-$34.15M
-$11.64M
-$707K
Net income attributable to common shareholders
-$6.43M
-$6.15M
-$4.06M
-$10.55M
-$8.52M
-$34.15M
-$11.64M
-$707K
EBITDA
-$4.24M
-$4.08M
-$1.14M
-$8.07M
-$6.1M
-$4.59M
-$2.75M
$1.14M
Basic earnings per share
-$0.31
-$0.28
-$0.19
-$0.50
-$0.41
-$1.65
-$0.56
-$0.03
Diluted earnings per share
-$0.31
-$0.28
-$0.19
-$0.50
-$0.41
-$1.65
-$0.59
-$0.03
Recent news
Company coverage with links to the original publishers.
PetMed (PETS) reported a quarterly loss of $0.31 per share, significantly worse than the consensus estimate of $0.11, representing a -181.82% earnings surprise. Revenue of $35.77 million also missed expectations. The company received a Zacks Rank #5 (Strong Sell) rating due to unfavorable estimate revisions. Shares have declined 60.9% year-to-date, and the Internet-Commerce industry ranks in the bottom 41% of sectors.
PetMed Express, Inc. (Nasdaq: PETS) announced it will report financial results for the fourth quarter and fiscal year ended March 31, 2026, on June 2, 2026 after market close, with a conference call and webcast at 4:30pm Eastern Time. The company also announced a strategic partnership with Rural King to launch pet pharmacy offerings across retail and digital channels.
Cardone Ventures submitted an unsolicited all-cash proposal of $4.25 per share to acquire PetMed Express, valuing the company at approximately $89 million. The offer targets all outstanding shares and aims to improve the pet pharmacy's performance under private ownership.
PetMeds launches a holiday product collection emphasizing pet health, wellness, and practical gifts, including grooming products, first aid kits, DNA tests, and supplements for dogs, cats, and horses.